Navigation Links
Not All Colon Cancer Patients Need Chemotherapy: Study
Date:5/16/2008

DNA mismatch in some early stage cases makes therapy of little benefit, shortens survival

FRIDAY, May 16 (HealthDay News) -- Colon cancer patients with a specific subset of the disease don't need to receive chemotherapy. In fact, not only does chemotherapy not benefit this group of patients, it may actually harm them, a new study found.

"If you are found to have [this type of colon cancer], then you should not be treated with chemotherapy. Surgery alone would be standard treatment," said Daniel Sargent, lead author of the study and a professor of biostatistics at the Mayo Clinic in Rochester, Minn.

"In our data, patients who have [this type of cancer] who had surgery alone had a 93 percent survival at five years. In our study, chemotherapy actually lowered survival to 75 percent. So, we have a group of patients who can be spared the toxicity, the expense and the inconvenience of treatment and have a very good outcome even without any [chemotherapy] treatment," Sargent said.

The findings, presented Thursday at the American Society of Clinical Oncology annual meeting, in Chicago, confirm previous research and now give physicians a clearer roadmap for treatment, the study authors said.

About 15 percent of colon cancer tumors are known as deficient DNA mismatch repair (dMMR) tumors, because they have lost the ability to repair DNA damage. This particular type of tumor seems to be less aggressive than other forms of colon cancer, the researchers said.

A study published by the same group of researchers in 2003 in the New England Journal of Medicine also found that this subset of patients did not benefit from standard chemotherapy for colon cancer. Because the finding was so novel, the results needed confirmation before they could be incorporated into clinical practice. This new study offers that confirmation, the researchers said.

"We're talking about patients with early stage colon cancer. These are patients who sometimes get chemo and sometimes do not," Sargent said. "We have sought for a long time to try to determine if there was a way to predict which patients might benefit from chemo and which might not."

But, Sargent added, "we felt that in order to really recommend this in clinical practice, we needed to validate it."

The new study analyzed data from 1,027 patients in the United States as well as Canada, France and Italy who had participated in previous trials. Sixteen percent had dMMR.

"The goal was to validate that the 15 percent of patients who have defective mismatch repair did not receive any benefit from 5-FU therapy, and that is indeed exactly what we found," Sargent said.

"We now feel this is appropriately validated for clinical use," he added.

In fact, there is already a simple test for this type of cancer.

"The test is available and, in a patient with stage 2 disease being considered for treatment with chemotherapy, we think that this test would be useful," Sargent said.

More information

The National Cancer Institute has more on colon cancer.



SOURCES: Daniel Sargent, Ph.D., professor of biostatistics, Mayo Clinic, Rochester, Minn.; May 15, 2008, presentation, American Society of Clinical Oncology annual meeting, Chicago


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Study Suggests Green Tea May Support the Medical Treatment of Stomach and Colon Cancer
2. Discovery of a novel mechanism for the development of colon cancer
3. Protein May Trigger Colon Cancer
4. Monoclonal antibody Hb3: A marker for colon cancer progression or as a therapeutic target?
5. $450,000 sweetener in colon cancer battle
6. Study finds that competency in colonoscopy requires experience with 150 cases or more
7. USC study finds evidence of gender-related differences in development of colon cancer
8. New Drug Duo Helps Cut Colon Cancer Risk
9. New Drug Duo Helps Fight Colon Cancer
10. New Treatments Help Fight Liver, Colon Cancer
11. Colon cancer risk perception associated with screening behavior
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma ... as the company,s second affiliate in Latin America . ... ... Astellas Farma Colombia ... ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
Breaking Medicine Technology: